Breaking News Instant updates and real-time market news.

XENT

Intersect ENT

$33.85

(0.00%)

08:13
01/08/18
01/08
08:13
01/08/18
08:13

Intersect ENT sees FY18 revenue $111M-$116M, consensus $113.82M

The company forecasts full year 2018 revenue in the range of $111 to $116 million, which would represent an increase of 15-20% over 2017 and which includes an estimated 8% contribution from SINUVA product sales. The outlook for first quarter 2018 revenue is in the range of $23.2M to $23.7M, and the company continues to expect to launch SINUVA commercially in 2Q18.

XENT Intersect ENT
$33.85

(0.00%)

05/31/17
NORL
05/31/17
DOWNGRADE
NORL
Market Perform
Intersect ENT downgraded to Market Perform from Outperform at Northland
09/11/17
BOFA
09/11/17
NO CHANGE
Target $40
BOFA
Buy
Intersect ENT price target raised to $40 from $33 at BofA/Merrill
BofA/Merrill analyst Bob Hopkins raised Intersect ENT's price target to $40 from $33 following strong data of Resolve I & II studies at the American Rhinologic Society meeting in Chicago over the weekend. The analyst said meta-analysis showed a statistically significant benefit vs. control for Intersect's Sinuva pipeline product and he expects FDA approval early in 2018. Hopkins rates Intersect a Buy.
12/11/17
PIPR
12/11/17
NO CHANGE
Target $35
PIPR
Overweight
Intersect ENT approval came earlier than expected at Piper Jaffray
After Intersect ENT announced that it has received approval from the FDA for the Sinuva Sinus Implant, Piper Jaffray analyst Matt O'Brien said this was earlier than his expectation for approval to come after the January PDUFA date assigned for the product. While he thinks Sinuva could significantly add to revenues long term, he cautions for "reasonable" expectations in 2018, noting the company still plans a launch in the second quarter and a slow roll out. O'Brien keeps an Overweight rating and $35 price target on Intersect ENT shares.
01/02/18
JPMS
01/02/18
UPGRADE
Target $43
JPMS
Overweight
Intersect ENT upgraded to Overweight from Neutral at JPMorgan
JPMorgan analyst Michael Weinstein upgraded Intersect ENT to Overweight and raised his price target for the shares to $43 from $32. Recent FDA approval of the company's Sinuva drug-eluting sinus implant should drive an acceleration in growth and enable Intersect to deliver a minimum of 25% compound annual revenue growth into 2021, Weinstein tells investors in a research note.

TODAY'S FREE FLY STORIES

TOL

Toll Brothers

$43.60

0.43 (1.00%)

06:00
05/22/18
05/22
06:00
05/22/18
06:00
Earnings
Toll Brothers sees FY18 revenue $6.64B-$7.31B, consensus $6.97B »

Based on FY 2018's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

GRUB

GrubHub

$103.64

-0.145 (-0.14%)

05:58
05/22/18
05/22
05:58
05/22/18
05:58
Recommendations
GrubHub analyst commentary  »

GrubHub price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 12

    Jun

ZTCOY

ZTE Corp.

$0.00

(0.00%)

05:58
05/22/18
05/22
05:58
05/22/18
05:58
Periodicals
U.S., China reach broad outline on deal to settle ZTE controversy, WSJ reports »

The U.S. and China have…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Sep

HURN

Huron

$38.30

0.65 (1.73%)

05:57
05/22/18
05/22
05:57
05/22/18
05:57
Conference/Events
Huron management to meet with William Blair »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 12

    Jun

TOL

Toll Brothers

$43.60

0.43 (1.00%)

05:57
05/22/18
05/22
05:57
05/22/18
05:57
Earnings
Toll Brothers reports Q2 EPS 72c, consensus 76c »

Reports Q2 revenue $1.6B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

WWE

WWE

$57.86

6.37 (12.37%)

05:56
05/22/18
05/22
05:56
05/22/18
05:56
Conference/Events
WWE management to meet with MKM Partners »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

WD

Walker & Dunlop

$56.10

1.07 (1.94%)

05:55
05/22/18
05/22
05:55
05/22/18
05:55
Conference/Events
Walker & Dunlop management to meet with JMP Securities »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 24

    May

  • 31

    May

BUD

AB InBev

05:55
05/22/18
05/22
05:55
05/22/18
05:55
Upgrade
AB InBev rating change  »

AB InBev upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MMM

3M

$201.75

2.8 (1.41%)

, BAYRY

Bayer

$0.00

(0.00%)

05:55
05/22/18
05/22
05:55
05/22/18
05:55
Conference/Events
American Thoracic Society to hold a conference »

ATS 2018 will be held in…

MMM

3M

$201.75

2.8 (1.41%)

BAYRY

Bayer

$0.00

(0.00%)

BDX

Becton Dickinson

$228.74

3.73 (1.66%)

BIIB

Biogen

$277.69

-2.66 (-0.95%)

STEM

Ticker changed to MBOT

$0.00

(0.00%)

TEVA

Teva

$21.09

-0.14 (-0.66%)

UTHR

United Therapeutics

$104.12

-2.2 (-2.07%)

VCYT

Veracyte

$6.45

(0.00%)

VRTX

Vertex

$156.15

-1.09 (-0.69%)

NBRV

Nabriva Therapeutics

$4.54

-0.89 (-16.39%)

GILD

Gilead

$67.63

-0.38 (-0.56%)

GSK

GlaxoSmithKline

$40.05

0.005 (0.01%)

HRC

Hill-Rom

$90.70

0.12 (0.13%)

INNV

Innovus Pharmaceuticals

$0.00

(0.00%)

DNA

Bought by RHHBY

$0.00

(0.00%)

CELG

Celgene

$74.69

-3.7 (-4.72%)

JAZZ

Jazz Pharmaceuticals

$166.01

-1.59 (-0.95%)

ISRG

Intuitive Surgical

$463.18

4.3 (0.94%)

INSM

Insmed

$26.34

-2.16 (-7.58%)

REGN

Regeneron

$296.58

-5.29 (-1.75%)

OCX

OncoCyte

$2.50

-0.05 (-1.96%)

FGEN

FibroGen

$52.55

1.45 (2.84%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 24

    May

  • 30

    May

  • 30

    May

  • 31

    May

  • 03

    Jun

  • 05

    Jun

  • 05

    Jun

  • 12

    Jun

  • 13

    Jun

  • 13

    Jun

  • 14

    Jun

  • 16

    Jun

  • 25

    Jun

  • 26

    Jun

  • 11

    Aug

  • 20

    Oct

  • 20

    Dec

CCJ

Cameco

$11.38

0.015 (0.13%)

05:54
05/22/18
05/22
05:54
05/22/18
05:54
Downgrade
Cameco rating change  »

Cameco downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TER

Teradyne

$38.17

0.77 (2.06%)

05:54
05/22/18
05/22
05:54
05/22/18
05:54
Conference/Events
Teradyne management to meet with Craig Hallum »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 30

    May

RTN

Raytheon

$213.95

2.88 (1.36%)

05:54
05/22/18
05/22
05:54
05/22/18
05:54
Downgrade
Raytheon rating change  »

Raytheon downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SYRS

Syros Pharmaceuticals

$11.96

-0.41 (-3.31%)

05:54
05/22/18
05/22
05:54
05/22/18
05:54
Conference/Events
Syros Pharmaceuticals management to meet with JMP Securities »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

SPSC

SPS Commerce

$71.88

0.11 (0.15%)

05:53
05/22/18
05/22
05:53
05/22/18
05:53
Conference/Events
SPS Commerce management to meet with Oppenheimer »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 24

    May

  • 29

    May

  • 12

    Jun

RDCM

Radcom

$19.65

0.25 (1.29%)

05:52
05/22/18
05/22
05:52
05/22/18
05:52
Conference/Events
Radcom management to meet with Needham »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 24

    May

  • 24

    May

  • 29

    May

INFO

IHS Markit

$51.60

0.13 (0.25%)

05:52
05/22/18
05/22
05:52
05/22/18
05:52
Upgrade
IHS Markit rating change  »

IHS Markit upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FITB

Fifth Third

$30.89

-2.66 (-7.93%)

05:51
05/22/18
05/22
05:51
05/22/18
05:51
Upgrade
Fifth Third rating change  »

Fifth Third upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QTM

Quantum

$3.62

-0.06 (-1.63%)

05:51
05/22/18
05/22
05:51
05/22/18
05:51
Conference/Events
Quantum management to meet with Lake Street »

Meeting to be held in Los…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 29

    May

FITB

Fifth Third

$30.89

-2.66 (-7.93%)

05:51
05/22/18
05/22
05:51
05/22/18
05:51
Upgrade
Fifth Third rating change  »

Fifth Third upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OTEX

OpenText

$34.10

0.1 (0.29%)

05:51
05/22/18
05/22
05:51
05/22/18
05:51
Conference/Events
OpenText management to meet with Benchmark »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

NVEE

NV5 Global

$60.60

0.6 (1.00%)

05:50
05/22/18
05/22
05:50
05/22/18
05:50
Conference/Events
NV5 Global management to meet with Lake Street »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 23

    May

  • 09

    Jun

  • 12

    Jun

  • 13

    Jun

M

Macy's

$34.60

0.63 (1.85%)

05:49
05/22/18
05/22
05:49
05/22/18
05:49
Upgrade
Macy's rating change  »

Macy's upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NCR

NCR Corp.

$31.30

0.11 (0.35%)

05:49
05/22/18
05/22
05:49
05/22/18
05:49
Conference/Events
NCR Corp. management to meet with Oppenheimer »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 23

    May

ONCE

Spark Therapeutics

$73.03

-3.69 (-4.81%)

, PFE

Pfizer

$35.79

0.15 (0.42%)

05:44
05/22/18
05/22
05:44
05/22/18
05:44
Hot Stocks
Spark Therapeutics, Pfizer announce data SPK-9001 ongoing Phase 1/2 trial »

Spark Therapeutics (ONCE)…

ONCE

Spark Therapeutics

$73.03

-3.69 (-4.81%)

PFE

Pfizer

$35.79

0.15 (0.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Jun

  • 10

    Sep

FMC

FMC Corporation

$91.30

-0.22 (-0.24%)

05:41
05/22/18
05/22
05:41
05/22/18
05:41
Hot Stocks
FMC Corporation awarded contract for two fertilizer plants in India »

TechnipFMC, in consortium…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.